文献速递淋巴瘤

大B细胞淋巴瘤患者CAR-T治疗后检测可测量残留病灶可预测缓解

Measurable residual disease detection after CAR-T may predict response in patients with large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2025-01-01

研究应用MAESTRO超灵敏肿瘤知情可测量残留病灶(MRD)检测法,对2018至2022年间在本机构接受阿基仑赛(axi-cel)治疗的28例大B细胞淋巴瘤患者(12个月持久缓解者15例、无缓解者13例)的140份样本进行循环肿瘤DNA(ctDNA)检测;输注后1周缓解者ctDNA较无缓解者显著下降(P < .001),第2周和第4周缓解者ctDNA接近0 ppm而无缓解者持续存在(各P < .001),证实高灵敏MRD检测用于早期识别进展高风险患者的可行性。

要点

  • 输注后1周,缓解者ctDNA较无缓解者显著下降(P < .001)。
  • 第2周和第4周,缓解者ctDNA接近0 ppm,无缓解者持续存在(各P < .001)。
  • 第0天高达21%的患者ctDNA分数<0.01%,灵敏度较低的检测无法监测。

核心结论

  • 结果证实通过ctDNA进行高灵敏MRD检测的可行性,可用于早期识别阿基仑赛治疗后疾病进展高风险患者。

研究设计与样本

  • 应用MAESTRO超灵敏肿瘤知情MRD检测法,对28例患者(12个月持久缓解者15例、无缓解者13例)的140份样本进行ctDNA检测。
  • 患者于2018年至2022年间在本机构接受阿基仑赛(axi-cel)治疗。
  • 缓解者与无缓解者基线肿瘤负荷相似。

主要发现

  • 输注后1周,缓解者ctDNA较无缓解者显著下降(P < .001)。
  • 第2周和第4周,缓解者ctDNA水平接近0 ppm,而无缓解者ctDNA持续存在(各P < .001)。
  • 第0天高达21%的患者ctDNA分数<0.01%,这些个体无法用灵敏度较低的检测进行ctDNA监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite responses of chimeric antigen receptor (CAR)-T cells in patients with relapsed/refractory large B-cell lymphoma (LBCL), over half of patients eventually relapse. Methods to detect early disease persistence are needed to identify patients at high risk of treatment failure. We recently developed MAESTRO, an ultrasensitive, tumor-informed measurable residual disease (MRD) assay, which can detect parts-per-million (ppm) levels of circulating tumor DNA (ctDNA) using minimal sequencing. We applied MAESTRO to 140 samples from 28 patients (15 durable responders at 12 months and 13 nonresponders) to identify treatment failure after axicabtagene ciloleucel (axi-cel), administered at our institution between 2018 and 2022. Responder and nonresponder patients had similar baseline tumor burden. By 1 week after infusion, responders had marked ctDNA reduction compared to nonresponders (P < .001). At weeks 2 and 4, responders had ctDNA levels approaching 0 ppm, whereas nonresponders had persistence of ctDNA (each P < .001). At day 0, up to 21% of patients had ctDNA fractions <0.01%; hence, these individuals would not have qualified for ctDNA monitoring with a less sensitive test. Our results confirm the feasibility of highly sensitive MRD detection by ctDNA for early identification of patients at high risk of disease progression from axi-cel.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Krasnow N, Maurer K, Song C, et al. Measurable residual disease detection after CAR-T may predict response in patients with large B-cell lymphoma. Blood Adv. 2025. PMID: 40706054. doi:10.1182/bloodadvances.2024015788

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。